



Cite this: *Analyst*, 2023, **148**, 1805

# Rapid detection and quantification of paracetamol and its major metabolites using surface enhanced Raman scattering†

Najla AlMasoud,<sup>a,b</sup> Taghrid S. Alomar,<sup>a,b</sup> Yun Xu,<sup>id</sup> <sup>b</sup> Cassio Lima<sup>id</sup> <sup>b</sup> and Royston Goodacre<sup>id</sup> <sup>\*b</sup>

Paracetamol (also known as acetaminophen) is an over-the-counter (OTC) drug that is commonly used as an analgesic for mild pain, headache, cold and flu. While in the short term it is a safe and effective medicine, it is sometimes used for attempted suicides particularly in young adults. In such circumstances it is important for rapid diagnosis of overdoses as antidotes can be given to limit liver damage from one of its primary metabolites *N*-acetyl-*p*-benzoquinone imine (NAPQI). Unfortunately, the demand for rapid and sensitive analytical techniques to accurately monitor the abuse of OTC drugs has significantly risen. Ideally these techniques would be highly specific, sensitive, reproducible, portable and rapid. In addition, an ideal point of care (PoC) test would enable quantitative detection of drugs and their metabolites present in body fluids. While Raman spectroscopy meets these specifications, there is a need for enhancement of the signal because the Raman effect is weak. In this study, we developed a surface-enhanced Raman scattering (SERS) methodology in conjunction with chemometrics to quantify the amount of paracetamol and its main primary metabolites (*viz.*, paracetamol sulfate, *p*-acetamidophenyl  $\beta$ -D-glucuronide and NAPQI) in water and artificial urine. The enhancement of the SERS signals was achieved by mixing the drug or xenometabolites with a gold nanoparticle followed by aggregation with 0.045 M NaCl. We found that the SERS data could be collected directly, due to immediate analyte association with the Au surface and colloid aggregation. Accurate and precise measurements were generated, with a limit of detection (LoD) of paracetamol in water and artificial urine at  $7.18 \times 10^{-6}$  M and  $2.11 \times 10^{-5}$  M, respectively, which is well below the limit needed for overdose and indeed normal levels of paracetamol in serum after taking 1 g orally. The predictive values obtained from the analysis of paracetamol in water and artificial urine were also excellent, with the coefficient of determination ( $Q^2$ ) being 0.995 and 0.996, respectively (1 suggests a perfect model). It was noteworthy that when artificial urine was spiked with paracetamol, no aggregating agent was required due to the salt rich medium, which led to spontaneous aggregation. Moreover, for the xenometabolites of paracetamol excellent LoDs were obtained and these ranged from  $2.6 \times 10^{-4}$  M to  $5 \times 10^{-5}$  M with paracetamol sulfate and NAPQI having  $Q^2$  values of 0.934 and 0.892 and for *p*-acetamidophenyl  $\beta$ -D-glucuronide this was slightly lower at 0.6437.

Received 15th February 2023,  
Accepted 13th March 2023

DOI: 10.1039/d3an00249g

[rsc.li/analyst](https://rsc.li/analyst)

## 1. Introduction

Paracetamol, also known as acetaminophen, *N*-acetyl-*p*-aminophenol or APAP, was first manufactured in 1878.<sup>1</sup> It is an active pharmaceutical ingredient (API) that has been commonly used as an analgesic for mild pain, headache, cold and

flu.<sup>2</sup> Paracetamol can be purchased over-the-counter in the form of tablets, capsules, suppositories, suspensions and solutions. The recommended daily dosage of this medication is 1–4 g per day and 50–75 mg per kg per day for adults and children, respectively.<sup>3,4</sup> It is widely accepted that this drug is not associated with the most frequently reported side effects of nonsteroidal anti-inflammatory drugs (NSAIDs).

Despite the wide use of paracetamol, exceeding the recommended maximum single dose of 7 g per day in adults and 150 mg kg<sup>-1</sup> in children may have life threatening implications and cause long-term damage and failure of vital organs, such as the liver. The normal serum level after taking 1 g paracetamol orally is 30 mg L<sup>-1</sup>, while for acute overdose victims this rises to 50–400 mg L<sup>-1</sup> serum.<sup>5</sup> In addition, other side effects

<sup>a</sup>Department of Chemistry, College of Science, Princess Nourah bint Abdulrahman University, Riyadh 11671, Saudi Arabia

<sup>b</sup>Centre for Metabolomics Research, Department of Biochemistry and Systems Biology, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, L69 7ZB, UK. E-mail: [roy.goodacre@liverpool.ac.uk](mailto:roy.goodacre@liverpool.ac.uk)

†Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d3an00249g>



of paracetamol misuse are skin rashes and suppression of blood sugar levels.<sup>6–8</sup> Paracetamol is converted into three major metabolites in the human body (Fig. 1) including an inactive glucuronide (52–57% of urinary metabolites), sulfate conjugates (30–44%) and *N*-acetyl-*p*-benzoquinone imine (NAPQI) (5–15%).<sup>9,10</sup> In case of acute overdose, the paracetamol toxicity is mainly due to NAPQI and this is due to depletion of glutathione which normally conjugates to NAPQI making it harmless.<sup>11</sup> The liver and to a less extent the kidney and intestines, are the major organs that are damaged severely by the metabolites of paracetamol.<sup>12</sup>

In order to minimise minor and major side effects of medications, it is vital to identify and quantify over-the-counter drugs in human biofluids to ensure whether compliance is met by users and providers. Many research studies use different methods for the quantification and characterisation of drugs. The routine clinical use of paracetamol for a number of mild health conditions, has resulted in the application of many analytical tools for drug identification and quantification. These include chromatography,<sup>13</sup> spectrophotometry<sup>14</sup> and electrochemical analysis.<sup>15</sup> Chromatography, in particular liquid chromatography, is widely used in the pharmaceutical industry to characterise drugs and this is due to its high resolution, precision and accuracy.<sup>16</sup> However, chromatography is destructive, pre-treatment of samples is time-consuming and large quantities of organic/inorganic solvents are consumed. As a result, there is a need for alternative methods to characterise drugs and their metabolites that are faster, more reliable and sustainable.<sup>17–20</sup> The ideal technique should have these features as well as being portable/handheld to enable point of care (PoC) use.

Raman spectroscopy is a vibrational analytical technique that has the advantage of providing a specific molecular pattern of a compound to enable identification and quantification. This analytical technique is non-invasive, increasingly available as portable devices and has been shown to be useful in the analysis of biofluids.<sup>21–23</sup> However, this technique

suffers from a weak signal and fluorescence from biological samples; in combination, these affect the quality of the data and limit its application in biological samples, such as urine.<sup>24</sup> One way to enhance the Raman signal significantly is to apply surface-enhanced Raman scattering (SERS). This enhancement requires the analyte to be in close contact with a roughened metal surface<sup>25–28</sup> such as gold/silver in colloidal suspensions and highly quantitative analysis has been readily reported.<sup>29–32</sup>

We have conducted extensive research in order to optimise SERS substrates for the detection of traces of drugs in human samples,<sup>33</sup> both illicit and legal.<sup>34,35</sup> Previous research has focused on the identification of both single and multiple analytes to detect various illicit drugs in body fluids using SERS. While there are reported of SERS on paracetamol,<sup>36,37</sup> most are qualitative and do not include the quantitative analyses of the primary metabolites of paracetamol. Therefore, the aim of this study was to develop a SERS based portable assay to quantify paracetamol and its major metabolites.

## 2. Materials and method

### 2.1 Chemicals

The chemicals used for sample preparations included silver nitrate (purity >99.99%), trisodium citrate (99%), sodium tetrahydridoborate, hydroxylamine hydrochloride (99%), chloroauric acid (99.9%), sodium chloride, artificial urine, paracetamol and its metabolites paracetamol sulfate potassium, *N*-acetyl-*p*-benzoquinone imine and *p*-acetamidophenyl  $\beta$ -D-glucuronide sodium salts (99%). All of these materials were purchased from Sigma-Aldrich (Dorset, UK). The chemical structure of paracetamol and its major primary metabolites are illustrated in Fig. 1.


### 2.2 Preparation of glassware

The glassware used for the preparation of gold and silver nanoparticles was cleaned using aqua regia (3 : 1, HCl/HNO<sub>3</sub>). Next, double distilled water was used to rinse the glassware to remove any remaining residues, and it was then allowed to dry at 50 °C.

### 2.3 Synthesis of metal nanoparticles

**Gold citrate colloid.** Gold nanoparticles were prepared according to the protocol published by Turkevich *et al.*<sup>38</sup> This involved vigorous stirring of a 100 mL volume of 50 mg HAuCl<sub>4</sub> solution with 850 mL of boiling water. Once the solution reached its boiling point, 50 mL of 1% trisodium citrate was added and the solution was allowed to boil and vigorous stirring remained for 30 min. At this point a deep red colour was seen and the resultant gold nanoparticle solution was then allowed to cool down.

**Silver hydroxylamine colloid.** The silver hydroxylamine colloid was prepared following the method published by Leopold and Lendl.<sup>39</sup> This involved the addition of 4.5 mL of sodium hydroxide solution (0.1 M) to 5 mL of hydroxylamine



**Fig. 1** The main pathways of paracetamol metabolism. The structures of the drug and its metabolites are shown and all of these analytes were used in this study.



hydrochloride solution ( $6 \times 10^{-2}$  M). Subsequently, 90 mL of silver nitrate ( $\text{AgNO}_3$ ) aqueous solution ( $1.11 \times 10^{-3}$  M) was added to the mixture rapidly. The resultant mixture was then shaken until it was completely homogeneous. This led to the production of a milky-grey colored solution.

**Silver borohydride colloid.**  $\text{AgNO}_3$  was reduced using  $\text{NaBH}_4$  aqueous solution. This was achieved by placing 102 mg per 100 mL of  $\text{AgNO}_3$  and 60 mg per 300 mL of  $\text{NaBH}_4$  on ice for 30 min independently. Once the solutions cooled down, they were combined and stirred vigorously together for 60 min, which resulted in the formation of a yellow colloid solution of silver nanoparticles.

The resultant colloids from the three methods were stable when poured into glass flasks. They were covered in foil and stored in a dark cupboard at room temperature for several weeks.

## 2.4 Nanoparticles characterisation

Different colloids were characterised by a UV-Vis spectrophotometer on a Jenway 7200 Visible 72 Series Diode Array Scanning Spectrophotometer (Cole-Parmer Ltd, Staffordshire, UK) (with a range of 335–800 nm). The UV-Vis absorbance spectra of gold nanoparticles are shown in Fig. S1.† In addition, scanning electron microscopy (SEM) was used to visualize the colloids using a Hitachi S-4800 microscope operating at a voltage of 1 kV: images of the same gold colloid have been reported elsewhere,<sup>40</sup> and as the silver colloids were not optimal for SERS (see below) the micrographs are not reported here.

## 2.5 Instrumentation

To collect SERS data, we used a DeltaNu Advantage portable Raman spectroscopy (DeltaNu, Laramie, WY, USA), equipped with a 785 nm HeNe laser and powered with an output of ~60 mW on the sample. This Raman device was calibrated daily using a polystyrene internal standard supplied by the instrument manufacturer. The spectral range used was 200–1800  $\text{cm}^{-1}$  and the laser exposure time was set to 30 s.

## 2.6 Sample preparation for SERS measurements

The following protocol was used for measuring paracetamol and its major metabolites: 250  $\mu\text{L}$  of each drug sample was mixed with 250  $\mu\text{L}$  of the colloid, followed by the addition of 50  $\mu\text{L}$  NaCl (0.5 M) or  $\text{KNO}_3$  (0.5 M) as the aggregating agents. The mixtures were then immediately placed in the DeltaNu Raman system and the spectral data were collected.

Initial experiments were carried out to optimize the SERS conditions. These involved the assessment of the three different colloids described above: gold citrate colloid, silver hydroxylamine colloid or silver borohydride. In addition, tests were conducted on whether NaCl or  $\text{KNO}_3$  was the best aggregating agent. Finally, after the analyte, colloid and aggregating agent were mixed spectra were collected after aggregation for 0 to 40 min in intervals of 5 min, to ascertain at which point the signal was strongest.

For quantitative SERS analysis paracetamol and its metabolites were dissolved in water individually at a series of concen-

trations ranging from 3 mM to 0.003 mM. In addition, the same range was used for paracetamol spiked into artificial urine, and for this experiment SERS measurements were conducted in both the presence or absence of the aggregating agent (NaCl).

## 2.7 Chemometrics analysis

After exporting the data off the DeltaNu spectrometers as ASCII files, MATLAB software R2021b (The Math Works Inc., Natick, MA, USA) was used to analyze the SERS spectral data. The SERS spectra were baseline corrected by using asymmetric least squares,<sup>41</sup> after which these SERS spectra were smoothed *via* a Savitzky–Golay filter using a 2nd order polynomial and a window width of 11 points. Finally the spectra were normalized by vector norm so that the sum of square of each spectrum equals 1 and subjected to unsupervised principal components analysis (PCA)<sup>42,43</sup> to visualize the natural patterns within these SERS data. Supervised partial least-squares regression (PLSR)<sup>44,45</sup> was used to quantify the concentration of paracetamol and its metabolites in the mixtures as described previously.<sup>20,31</sup> As the concentration ranges of these analytes spanned over two orders of magnitude the natural log (ln) of the output was taken to normalise the data and to stabilize the variance. The PLSR models were trained and validated using a *k*-fold double cross-validation procedure where *k* is the number of different concentrations within each analyte dilution range.<sup>46</sup> Finally, the limit of detection (LoD) of paracetamol and its metabolites were also estimated based on the predictions PLSR models on the test sets only using the method described in ref. 47. For PLSR modelling and tests, the SERS spectra were pre-processed by standard normal variate (SNV) normalization only so that each spectrum had a mean of 0 and standard deviation of 1. This is to minimize steps of pre-processing and reduce risk of over-fitting associated to pre-processing methods and their parameters.

# 3. Results and discussion

## 3.1 SERS optimisation experiments

SERS is a technique that uses nanoscale roughened metal surfaces, such as gold and silver, in order to boost the rather weak Raman signal. This study started with the optimisation of SERS in order to generate not only enhanced signals but spectra that were reproducible. The optimisation of SERS was carried out as follows: (a) the most suitable colloid was determined from three different nanoparticle preparations; (b) the most compatible aggregating agent between NaCl and  $\text{KNO}_3$  was determined; and (c) the time taken for the analyte (paracetamol in this case for the optimisation experiments) to associate with the metal surface and aggregation agent was recorded.

Step (a) involved the synthesis of three different colloids including – silver borohydride, silver hydroxylamine and gold citrate – in order to investigate the optimal metal surface for SERS along with the assessment of the two aggregating agents (step (b)). Raman bands were observed using all three SERS



substrates when detecting paracetamol (Fig. S2†). It is noteworthy that the SERS signal from paracetamol was noticeably different for each of the three colloids, and for silver hydroxylamine and silver borohydride colloids the spectra were non-reproducible and thus unreliable. By contrast, it can be seen that the gold nanoparticles gave highly reproducible signals as the three replicate spectra overlapped when either NaCl or KNO<sub>3</sub> was used as the aggregating agent (Fig. S2†). Both combinations gave similar SERS spectra indicating that the effect is nanoparticle dependent rather than being contingent on the aggregating agent. Close inspection of the spectra in Fig. S2† showed that when NaCl was used as the aggregating agent the most reproducible signals were observed. As a result, gold nanoparticles were utilized in subsequent investigations of paracetamol and its metabolites, along with employing 0.045 M NaCl (total within the sample) as the aggregating agent.

After choosing the colloid-aggregating agent pair, the final step (c) involved investigating the effect of analyte, colloid and aggregating agent association on the time required to observe SERS signals. Paracetamol (3 mM) was mixed with the gold colloid, followed by the addition of 50  $\mu$ L of 0.5 M NaCl as the aggregating agent under ambient conditions (*i.e.* RT) for association to occur. Analysis of each mixture was carried at 5-minute intervals for a duration of 0 to 40 min. Plots of the raw SERS spectra during this time frame for paracetamol are shown in Fig. S3.† All spectra in this time series show very similar bands and it was found that in the first 10 min of association, there was no obvious change in the SERS signal intensity and this implies that the analyte (paracetamol) associated rapidly with the gold surface. After 10 min there was a slight decrease in the signal intensity which suggests that upon aggregation larger aggregates were precipitating out of suspension. Thus, for all consequent analyses, the association of samples took place at 0 min, hence the sample was analyzed immediately.

### 3.2 Limit of detections for paracetamol and its major metabolites

As determined and reported above the optimal SERS protocol to quantify the amount of paracetamol in a given sample was determined using gold colloid prepared by reduction of chloroauric acid with citrate ions and 0.045 M NaCl as the aggregating agent. The resultant SERS data were collected immediately; *i.e.*, immediately after 0 min of preparation for each sample. Using this SERS protocol, we generated a dilution series of paracetamol and then each of its metabolites to determining the limit of detection (LoD) for each analyte.

For each of the four analytes a combination of visible inspection of the dilution series along with PCA was used to assess whether there was an obvious trend in PCA scores space that was related to the concentration of the analyte under investigation. The corresponding PCA loadings plots were then used to assess the most diagnostic peaks. This was then followed by PLSR modelling to predict the level of the drug or its xenometabolites and in these plots only the test sets are plotted from the *k*-fold cross validation procedure used. These

PLSR models were then used to estimate the LoDs for each analyte.

**Paracetamol in water.** The stock solution of paracetamol (3.3 mM) was diluted in water to 0.0009 mM. Fig. 2A shows the 16 SERS spectra that were collected from the following analyte concentrations: 3, 2, 1, 0.9, 0.8, 0.5, 0.3, 0.009, 0.007, 0.005, 0.004, 0.003, 0.002, 0.001, 0.0009 mM. It can be noted that the peaks observed at 860 cm<sup>-1</sup> and 1202 cm<sup>-1</sup> depend on the concentration of paracetamol. Thus, higher intensity peaks are observed at 3.3 mM and the intensity decreases as the concentration of the paracetamol decreases in the sample.


Further analysis using PCA was carried out to analyze SERS spectra of paracetamol in water (Fig. 2B). The PCA scores plot shows a clear trend along the PC-1 axis from positive to negative scores which correlates with decreasing concentrations of paracetamol. In the PCA plot, the first principal component (PC-1) explains the most variance within the data, so this is highly significant and accounts for 90.3% of the TEV (total explained variance). By contrast, the variance associated with PC-2 is relatively low (4.4%). Note that the replicate spectra cluster very closely together in the PCA scores plot which shows that using our optimal SERS protocol we achieved high reproducibility of signals. Furthermore, inspection of the loadings plot (Fig. 2C) showed two peaks were highly characteristic for paracetamol and these were at around 860 cm<sup>-1</sup> and 1202 cm<sup>-1</sup>. The peak at 860 cm<sup>-1</sup> corresponds to the aromatic ring bend (C–H out-of-plane skeletal deformation) in paracetamol.<sup>48</sup> In accordance with the electromagnetic selection rules the C–H stretching mode should be relatively enhanced when the C–H bond is perpendicular to the metal surface plane, as compared with the case in which the C–H bond lies parallel to the surface.<sup>49</sup>

Next the whole range of the SERS spectra (*i.e.*, 200–1800 cm<sup>-1</sup>) were used to construct PLSR models in order to test the ability of SERS to quantify paracetamol at low concentration in water. The PLSR predictions for paracetamol concentrations are shown in Fig. 2D. This figure illustrates excellent predictive values, with  $Q^2$  of 0.99 in predictions in a natural logarithm scaled concentration and  $Q^2$  of 0.95 when these predictions were reverted back to original scale (in moles). This shows an excellent agreement between predicted and corresponding known concentrations of test set samples as the closer the  $Q^2$  value to 1, the better the predictions. Furthermore, the root means square error of cross validation (RMSECV) was  $2.12 \times 10^{-4}$  M, and the LoD was found to be  $7.18 \times 10^{-6}$  M. This LoD is lower than the LoD that was reported in a previous study on paracetamol using SERS.<sup>50</sup> Note as mentioned above the normal serum level after taking 1 g paracetamol orally is 30 mg L<sup>-1</sup> ( $\sim 2 \times 10^{-4}$  M), while for acute overdose victims this rises to 50–400 mg L<sup>-1</sup> ( $3.3 \times 10^{-4}$  M to  $2.6 \times 10^{-3}$  M) serum,<sup>5</sup> so these detection limits are clinically useful and much faster than liquid chromatography.

**Metabolites of paracetamol in water.** Whilst determining and quantifying paracetamol is of paramount importance it is also useful to assess the major metabolites that occur when paracetamol is modified in the human liver.<sup>5</sup> This is especially important for *N*-acetyl-*p*-benzoquinone imine (NAPQI), as







**Fig. 2** (A) A series of SERS spectra of paracetamol in water at different concentration; spectra are offset for clarity. (B) PCA scores plot of SERS data acquired from paracetamol in water at different concentrations; TEV refers to total explained variance. (C) The corresponding PC-1 loadings plot (green line), with SERS spectra of paracetamol in water (blue) and the matrix (brown line; this has been multiplied by  $(-1)$  for clarity). (D) PLSR quantitative output generated using SERS data from paracetamol in water; data shown are the test set outputs only from the  $k$ -fold validation procedure.

while it only accounts for 5–15% of the primary metabolites of paracetamol,<sup>9,10</sup> in acute overdose cases acute liver toxicity leading to drug-induced liver injury (DILI) and then death is mainly due to NAPQI.<sup>12</sup> The dangerous NAPQI metabolite builds up in the body as it cannot be depleted and thus detoxified with glutathione<sup>11</sup> as it is in short supply. Thus, rapid quantification of NAPQI and other paracetamol metabolites may aid in knowing how long the overdose was taken and whether treating with *N*-acetylcysteine is needed to replenish glutathione.<sup>51</sup>

The optimised SERS protocol was further used to detect metabolites of paracetamol in water. For this purpose, three different metabolites were investigated including: *p*-acetamidophenyl  $\beta$ -D-glucuronide, paracetamol sulfate as well as NAPQI. Fig. 3 illustrates SERS spectra for all three paracetamol metabolites along with paracetamol and the matrix. Despite the similarities regarding their chemical structure, these SERS spectra from all four analytes displayed distinct spectral features, which could be associated with the different chemical conjugates due to glucuronidation or sulfation and for NAPQI hydroxylation and structural rearrangement. By contrast, these


differences could also be due to orientation effects resulting in different molecule adsorption onto the metal surface as reported by Lombardi and Birke;<sup>52</sup> note, there is no direct evidence of this.

In all of these experiments we include the matrix. This is the colloid after aggregation without the addition of any analyte. Thus, the peaks seen in the spectrum in Fig. 3E are not analyte but belong to citrate which is the capping agent that remains on the gold surface after metal reduction during nanoparticle formation.

**Quantification of paracetamol metabolites.** Serial dilutions were carried out on each sample of the three metabolites to calculate the working concentration range that was efficient for SERS. It was found that *p*-acetamidophenyl  $\beta$ -D-glucuronide was diluted from 1 mM to 0.009 mM, whereas paracetamol sulfate and NAPQI were diluted from 1.9 mM to 0.2 mM. For all of these three analytical replicates were performed.

Using *p*-acetamidophenyl  $\beta$ -D-glucuronide in water as an example the next stage of the analysis was to determine quantitative information that could be extracted from the SERS spectra of this metabolite. Fig. 4A shows the multiple peaks at





**Fig. 3** SERS spectra of (A) paracetamol sulfate potassium, (B) *N*-acetyl-*p*-benzoquinone imine, (C) *p*-acetamidophenyl  $\beta$ -D-glucuronide, (D) paracetamol and (E) matrix (i.e., the nanoparticles and aggregating agent alone without any analyte). SERS conditions used: gold nanoparticles with 0.045 M NaCl as the aggregating agent, and the collection time was 30 s.

606, 860, 1202 and 1270  $\text{cm}^{-1}$  in the baseline-corrected SERS spectra of *p*-acetamidophenyl  $\beta$ -D-glucuronide decreased in intensity with respect to concentrations of the analyte in the solutions. The data obtained from SERS was further investigated by PCA (Fig. 4B). The PCA score plot for *p*-acetamidophenyl  $\beta$ -D-glucuronide demonstrated a clear concentration-dependent trend, which is reflected on PC1 with TEV of 83.8%. Concentrations of *p*-acetamidophenyl  $\beta$ -D-glucuronide less than 0.06 mM were separated slightly on PC2 (TEV of 8.5%) indicating at lower concentrations the SERS spectra were less reproducible than those >0.06 mM. PC-1 loadings plot (Fig. 4C) showed that peaks at 1202 and 1270  $\text{cm}^{-1}$  were the most significant vibrational bands contributing to the separation.

Furthermore, other bands were observed and were possibly specific to the matrix because it is anticipated that *p*-acetamidophenyl  $\beta$ -D-glucuronide interacts more strongly with the gold nanoparticles. In light of the PCA, next PLSR modelling was carried out for the quantification of *p*-acetamidophenyl  $\beta$ -D-glucuronide using the SERS spectral data. The PLSR predictions for the glucuronide conjugated metabolite concentrations are shown in Fig. 4D. These predictions showed excellent predictive accuracies, with  $Q^2$  of 0.9379, RMSECV of  $2.88 \times 10^{-4}$  M and a LoD at  $4.97 \times 10^{-5}$  M.

The two other metabolites were also analyzed as described above. Briefly, Fig. S4A and D† show a concentrations profile and the effects on the SERS spectra of paracetamol sulfate and NAPQI. After PCA (not shown) the corresponding PCA loading plots were inspected (Fig. S4B and E†) for these two metabolites in order to detect significant peaks. The PCA loading


plots correlated to the wavenumber shifts from the analytes as they replaced the citrate on the gold surface. PLSR models were also employed and predictions were generated as shown in Fig. S4C and F.† It was apparent from these observations that there was an abundance of information within the SERS spectra, allowing excellent predictions of the concentrations of metabolites in the samples. In general, very low root means square error (RMSE) of cross validation (RMSECV) confirmed a high prediction accuracies for paracetamol and its three metabolites (Table 1). For paracetamol and *p*-acetamidophenyl  $\beta$ -D-glucuronide, the concentration ranged over three orders of magnitude, therefore log-scaling was needed to prevent model being dominated by high concentration samples. By contrast, for paracetamol sulfate potassium and NAPQI, the range of concentration varied within one order of magnitude and a log-scaling pre-process was not necessary. In fact, log-scaling had adverse effect when applied to these two sets of data on the accuracies in predicting test set, resulted in much higher RMSECV and lower  $Q^2$  (Table 1). The results showed that the concentrations of samples in both low and high concentrations had been over estimated, and this suggests that when variance stabilization was not necessary, a forced log-linear modelling had resulted in extra error in predictions.

**Paracetamol in artificial urine.** The final stage was to establish the limit of detection of paracetamol in artificial urine (Fig. 5). This was chosen as a mimic of a human body fluid and initial experiments showed that we were unable to generate any SERS spectra of paracetamol in serum (data not shown). The same protocol that was used for the quantification of paracetamol in water, was also carried out to quantify the amount of paracetamol in artificial urine. SERS spectra, Fig. 5A, clearly show that the ring breathing mode at around 860  $\text{cm}^{-1}$  and 1202  $\text{cm}^{-1}$  can be used as reference markers to quantify the amount of paracetamol in artificial urine samples at these 16 different concentrations.

The data collected from the spiked urine samples, were analyzed using PCA (Fig. 5B) where there was a clear trend in PCA space where PC-1 correlated with the concentration of paracetamol. The corresponding PC-1 loading plot (Fig. 5C) also highlighted 860 and 1202  $\text{cm}^{-1}$  as being important contributors to this model. Furthermore, PLSR model predictions of the collected data were plotted against corresponding known concentrations as shown in Fig. 5D, which showed excellent agreement between predicted concentrations and corresponding known concentrations. The figures of merit from PLS in terms of  $Q^2$ , RMSECV and LoD are reported in Table 2.

We also collected a series of SERS spectra from urine alone, along with a spike of paracetamol (with and without NaCl as the aggregating agent), along with paracetamol in water as a comparison (Fig. S5†). It is clear from these spectra that there are SERS peaks that are present in urine which are also observed when paracetamol is present. Many of these peaks have been described previously<sup>19,53–55</sup> and many can be assigned to uric acid ( $\sim 640$   $\text{cm}^{-1}$ : =O–N deformation;  $\sim 890$   $\text{cm}^{-1}$ : N–H bending), hypoxanthine ( $\sim 720$   $\text{cm}^{-1}$ : C–H stretching) and tryptophan ( $\sim 680$   $\text{cm}^{-1}$ ;  $\sim 1360$   $\text{cm}^{-1}$  (also





**Fig. 4** (A) A series of SERS spectra of *p*-acetamidophenyl β-D-glucuronide in water at different concentration; spectra are offset for clarity. (B) PCA scores plot of SERS data acquired from *p*-acetamidophenyl β-D-glucuronide in water at different concentrations; TEV refers to total explained variance. (C) Corresponding PC-1 loadings plot (green line), with SERS spectra of *p*-acetamidophenyl β-D-glucuronide in water (blue) and matrix (brown line; this has been multiplied by (−1) for clarity). (D) PLSR quantitative output generated using SERS data from *p*-acetamidophenyl β-D-glucuronide in water; data shown are the test set outputs only from the *k*-fold validation procedure.

**Table 1** The similarity between the PLSR models showing their reproducibility and accuracy of predicting paracetamol and its major metabolites concentrations in water

Analyte	$Q^2(\ln)$	$Q^2$	RMSECV	LoD
Paracetamol	0.9947	0.9590	$2.12 \times 10^{-4}$ M	$7.18 \times 10^{-6}$ M
<i>p</i> -Acetamidophenyl β-D-glucuronide	0.9379	0.6437	$2.88 \times 10^{-4}$ M	$4.97 \times 10^{-5}$ M
Paracetamol sulfate potassium	0.8538	0.2475	$3.90 \times 10^{-4}$ M	$3.28 \times 10^{-4}$ M
NAPQI	0.7263	0.0253	$4.21 \times 10^{-4}$ M	$3.91 \times 10^{-4}$ M
Paracetamol sulfate potassium (without log-scaling)	—	0.9339	$1.16 \times 10^{-4}$ M	$2.56 \times 10^{-4}$ M
NAPQI (without log-scaling)	—	0.8920	$1.40 \times 10^{-4}$ M	$2.81 \times 10^{-4}$ M


$Q^2(\ln)$  is the coefficient of determination of natural log-scaled PLSR model predictions;  $Q^2$  is the coefficient of determination calculated after the predictions of log-scaled PLSR model predictions had been scaled back to their original scale using exponential function, RMSECV is the root-mean-squared error of cross-validation, calculated in the original scale (M); LoD is the estimated limit of detection using the corresponding PLSR model as described in the text.

ascribed to guanine)). It is noteworthy that despite these SERS urine peaks being present when paracetamol is analysed, they are not used in quantitative modelling as illustrated in the PCA loading plots in Fig. 5C (green line).

During these experiments we observed that spontaneous aggregation occurred which is most likely due to the presence

of salts in artificial urine. Therefore, further experiments were carried out on these spiked samples without the addition of the NaCl aggregating agent. The same results as reported above in terms of visible inspection of the SERS spectra (Fig. S6A†), use of PCA (Fig. S6B and C†) and PLSR (Fig. S6D†).





**Fig. 5** (A) A series of SERS spectra of paracetamol in artificial urine at different concentration; spectra are offset for clarity. (B) PCA scores plot of SERS data acquired from paracetamol in artificial urine at different concentrations. (C) Corresponding PC-1 loadings plot (green line), with SERS spectra of paracetamol (blue) and matrix (brown line; this has been multiplied by (−1) for clarity). Spectra are offset for clarity. (D) PLSR quantitative output generated using SERS data from paracetamol in artificial urine; data shown are the test set outputs only from the *k*-fold validation procedure.

**Table 2** The similarity between the PLSR models showing their reproducibility and accuracy of predicting paracetamol and its major metabolites concentrations in water and spiked in urine

Analytes	$Q^2(\ln)$	$Q^2$	RMSECV	LoD
Paracetamol in urine with aggregation agent	0.9956	0.9801	$1.48 \times 10^{-4}$ M	$2.24 \times 10^{-5}$ M
Paracetamol in urine without aggregation agent	0.9954	0.9897	$1.06 \times 10^{-4}$ M	$2.11 \times 10^{-5}$ M

$Q^2(\ln)$  is the coefficient of determination of natural log-scaled PLSR model predictions;  $Q^2$  is the coefficient of determination calculated after the predictions of natural log-scaled PLSR models had been scaled back to their original scale using exponential functions; RMSECV is the root-mean-squared error of cross-validation, calculated in the original scale (M); LoD is the estimated limit of detection using the corresponding PLSR model as described in the text.

Table 2 compares the values that were generated from the PLS models for paracetamol in urine with and without an aggregation agent. Surprisingly, the  $Q^2(\ln)$  and  $Q^2$  values for paracetamol in artificial urine were slightly higher than in water. In addition, both the RMSECV and LoDs were lower for artificial urine. These results are likely due to be due to an increase in colloid aggregation, in addition to an enhanced association of paracetamol with a gold surface, which is most likely due to the presence of salts found in artificial urine samples. The artificial urine used in this study was rich in

salts, such as NaCl as well as many other salts (Table S1†). These observations lead to the interesting prospect of using a combination of salts in future experiments to further enhance SERS signals through optimal aggregation.

## 4. Conclusion

The use of rapid and sensitive portable/handheld techniques to measure the concentration of drugs and their metabolites is





vital, especially in drug overdoses where administration of the most appropriate antidote is essential and time limited. Such technology would reduce unwanted side effects would be quickly detected and prevented. Quantification of drugs and their metabolites is typically conducted by using LC-MS. However, this is costly, labor and time intense and samples generally need to be transported to a dedicated laboratory which means that results are retrospective. Thus, alternative portable techniques are in urgent demand for the rapid quantification of drugs in biofluids. For this purpose, we chose paracetamol as the model drug and its three main metabolites including NAPQI which can cause drug-induced liver injury. These analytes were subsequently analysed using Raman spectroscopy. However, despite this method being reproducible, portable, robust, less laborious and time efficient, the scattering process of Raman is very weak, therefore we enhanced the Raman signal using a gold colloid to effect SERS. After optimisation of the SERS conditions multivariate data analysis was conducted using PCA and PLSR to look at trends in the SERS data and to quantify paracetamol and its major metabolites in a series of samples where the target analyte was diluted typically from 3 mM to 0.003 mM. The predictions showed excellent predictive values of paracetamol in water as well as artificial urine, and all three metabolites could also be readily quantified in water. To illustrate that all four analytes can be observed in a single mixture we also generated a SERS spectrum of all four analytes together in water. It is clear from Fig. S7† that the multiplexed spectra of all four analytes contains clear features (peaks) that can be assigned to the pure drug and drug metabolite spectra. It was noted that there was no need to add an aggregating agent to the spiked artificial urine with paracetamol, which is likely because of the salt rich medium in the urine and we shall be exploring mixed salts in the future for enhanced aggregation and SERS. Future suggested studies will also focus on developing suitable pre-sample treatment methods on the different compounds found in blood.

Finally, while there is some discussion in the field as to the reproducibility of SERS for generating quantitative data from target analytes in mixtures, there are several excellent reviews have highlighted the use of internal standards that can be used to compensate for any variations due to concentration of analytes-nanoparticles and laser power within the system.<sup>30,56–58</sup> These strategies have been used within clinical sciences and the interested reader will find details within these reviews.

## Author contributions

Conceptualization, RG; methodology, RG, NA and TSA; formal analysis, CL and YX; resources, RG; data curation, CL; writing—original draft preparation, NA; writing—review and editing, CL, YX, TSA and RG; funding acquisition, Princess Nourah Bint Abdulrahman University.

## Conflicts of interest

The authors declare no conflict of interest.

## Acknowledgements

NA and TSA thank Princess Nourah bint Abdulrahman University for supporting this research through scholarship program for funding and support.

## References

- 1 H. N. Morse, *Ber. Dtsch. Chem. Ges.*, 1878, **11**, 232–233.
- 2 C. Thompson, M. C. Davies, C. J. Roberts, S. J. Tendler and M. J. Wilkinson, *Int. J. Pharm.*, 2004, **280**, 137–150.
- 3 L. L. Mazaleuskaya, K. Sangkuhl, C. F. Thorn, G. A. FitzGerald, R. B. Altman and T. E. Klein, *Pharmacogenet. Genomics*, 2015, **25**, 416.
- 4 A. R. Temple, B. R. Temple and E. K. Kuffner, *Clin. Ther.*, 2013, **35**, 1361–1375.e1345.
- 5 J. A. Marx, R. Hockberger and R. Walls, *Rosen's Emergency Medicine: Concepts and Clinical Practice*, Elsevier, 2010, vol. 2.
- 6 S. R. Rose, *Am. J. Health-Syst. Pharm.*, 1994, **51**, 3065–3068.
- 7 J. D. Perkins, *Liver Transplant.*, 2006, **12**, 682–686.
- 8 N. AlRuwalli, F. Zaidan, A. AlFattani and S. Alenazi, *Int. J. Pediatr. Adolesc. Med.*, 2022, **9**, 62–65.
- 9 L. Prescott, *Drugs*, 1983, **25**, 290–314.
- 10 M. R. McGill and H. Jaeschke, *Pharm. Res.*, 2013, **30**, 2174–2187.
- 11 M. J. Hodgman and A. R. Garrard, *Crit. Care Clin.*, 2012, **28**, 499–516.
- 12 J. G. Bessems and N. P. Vermeulen, *Crit. Rev. Toxicol.*, 2001, **31**, 55–138.
- 13 A. F. El-Yazbi, K. M. Guirguis, M. M. Bedair and T. S. Belal, *Drug Dev. Ind. Pharm.*, 2020, **46**, 1853–1861.
- 14 E. A. Abdelaleem, I. A. Naguib, E. S. Hassan and N. W. Ali, *Anal. Chem. Lett.*, 2016, **6**, 13–23.
- 15 S. J. Saleem and M. Guler, *Electroanalysis*, 2019, **31**, 2187–2198.
- 16 M. Gumustas, S. Kurbanoglu, B. Uslu and S. A. Ozkan, *Chromatographia*, 2013, **76**, 1365–1427.
- 17 M. A. Bakkar, H. Nawaz, M. I. Majeed, A. Naseem, A. Ditta, N. Rashid, S. Ali, J. Bajwa, S. Bashir and S. Ahmad, *Spectrochim. Acta, Part A*, 2021, **245**, 118900.
- 18 T. De Beer, W. Baeyens, A. Vermeire, D. Broes, J. P. Remon and C. Vervaet, *Anal. Chim. Acta*, 2007, **589**, 192–199.
- 19 A. Subaihi, L. Almanqur, H. Muhamadali, N. AlMasoud, D. I. Ellis, D. K. Trivedi, K. A. Hollywood, Y. Xu and R. Goodacre, *Anal. Chem.*, 2016, **88**, 10884–10892.
- 20 H. Muhamadali, M. Chisanga, A. Subaihi and R. Goodacre, *Anal. Chem.*, 2015, **87**, 4578–4586.
- 21 K. J. Ember, M. A. Hoeve, S. L. McAughrrie, M. S. Bergholt, B. J. Dwyer, M. M. Stevens, K. Faulds, S. J. Forbes and C. J. Campbell, *npj Regener. Med.*, 2017, **2**, 1–10.



- 22 D. I. Ellis, D. P. Cowcher, L. Ashton, S. O'Hagan and R. Goodacre, *Analyst*, 2013, **138**, 3871–3884.
- 23 C. A. F. de Oliveira Penido, M. T. T. Pacheco, I. K. Lednev and L. Silveira Jr., *J. Raman Spectrosc.*, 2016, **47**, 28–38.
- 24 J. Caillaud, C. De Bleye, E. Dumont, P.-Y. Sacré, L. Netchacovitch, Y. Gut, M. Boiret, Y.-M. Ginot, P. Hubert and E. Ziemons, *J. Pharm. Biomed. Anal.*, 2018, **147**, 458–472.
- 25 M. Fleischmann, P. J. Hendra and A. J. McQuillan, *Chem. Phys. Lett.*, 1974, **26**, 163–166.
- 26 Y. Lu, L.-W. Wu, W. Cao and Y.-F. Huang, *Anal. Chem.*, 2022, **15**, 6011–6016.
- 27 W. Smith, *Chem. Soc. Rev.*, 2008, **37**, 955–964.
- 28 C. De Bleye, E. Dumont, E. Rozet, P.-Y. Sacré, P.-F. Chavez, L. Netchacovitch, G. Piel, P. Hubert and E. Ziemons, *Talanta*, 2013, **116**, 899–905.
- 29 L. Gozdziński, A. Rowley, S. A. Borden, A. Saatchi, C. G. Gill, B. Wallace and D. K. Hore, *Int. J. Drug Policy*, 2022, **102**, 103611.
- 30 R. Goodacre, D. Graham and K. Faulds, *TrAC, Trends Anal. Chem.*, 2018, **102**, 359–368.
- 31 D. P. Cowcher, Y. Xu and R. Goodacre, *Anal. Chem.*, 2013, **85**, 3297–3302.
- 32 S. Adomavičiūtė, M. Velička and V. Šablinskis, *Plasmonics in Biology and Medicine XVI*, Proc. SPIE, 2019, vol. 10894, p. 108940E.
- 33 C. Levene, E. Correa, E. W. Blanch and R. Goodacre, *Anal. Chem.*, 2012, **84**, 7899–7905.
- 34 S. Mabbott, A. Eckmann, C. Casiraghi and R. Goodacre, *Analyst*, 2013, **138**, 118–122.
- 35 S. Mabbott, E. Correa, D. P. Cowcher, J. W. Allwood and R. Goodacre, *Anal. Chem.*, 2013, **85**, 923–931.
- 36 E. de Barros Santos, E. C. N. L. Lima, C. S. de Oliveira, F. A. Sigoli and I. O. Mazali, *Anal. Methods*, 2014, **6**, 3564–3568.
- 37 S. Farquharson, C. Brouillette, W. Smith and C. Shende, *Front. Chem.*, 2019, **7**, 706.
- 38 J. Turkevich, P. C. Stevenson and J. Hillier, *Discuss. Faraday Soc.*, 1951, **11**, 55–75.
- 39 N. Leopold and B. Lendl, *J. Phys. Chem. B*, 2003, **107**, 5723–5727.
- 40 T. S. Alomar, N. AlMasoud, Y. Xu, C. Lima, B. Akbali, S. Maher and R. Goodacre, *Sensors*, 2022, **22**, 7832.
- 41 P. H. Eilers, *Anal. Chem.*, 2004, **76**, 404–411.
- 42 R. Vidal, Y. Ma and S. S. Sastry, *Generalized Principal Component Analysis*, Springer, 2016, pp. 25–62.
- 43 H.-P. Wang, P. Chen, J.-W. Dai, D. Liu, J.-Y. Li, Y.-P. Xu and X.-L. Chu, *TrAC, Trends Anal. Chem.*, 2022, 116648.
- 44 P. Geladi and B. R. Kowalski, *Anal. Chim. Acta*, 1986, **185**, 1–17.
- 45 X. Zhao, N. Wang, M. Zhu, X. Qiu, S. Sun, Y. Liu, T. Zhao, J. Yao and G. Shan, *Molecules*, 2022, **27**, 1707.
- 46 K. Roy and P. Ambure, *Chemom. Intell. Lab. Syst.*, 2016, **159**, 108–126.
- 47 A. C. Olivieri, H. C. Goicoechea and F. A. Iñón, *Chemom. Intell. Lab. Syst.*, 2004, **73**, 189–197.
- 48 M. Elbagerma, H. Edwards, T. Munshi and I. Scowen, *CrystEngComm*, 2011, **13**, 1877–1884.
- 49 L. Andronie, S. Cîntă Pinzaru, N. Peica, N. Leopold and O. Cozar, *Stud. Univ. Babeş-Bolyai, Phys.*, 2009, **2**, 51–57.
- 50 Z. Mukanova, K. Gudun, Z. Elemessova, L. Khamkhash, E. Ralchenko and R. Bukasov, *Anal. Sci.*, 2018, **34**, 183–187.
- 51 E. Piperno and D. Berssenbruegge, *Lancet*, 1976, **308**, 738–739.
- 52 J. R. Lombardi and R. L. Birke, *J. Phys. Chem. C*, 2008, **112**, 5605–5617.
- 53 A. Bonifacio, S. Cervo and V. Sergo, *Anal. Bioanal. Chem.*, 2015, **407**, 8265–8277.
- 54 C. Westley, Y. Xu, B. Thilaganathan, A. J. Carnell, N. J. Turner and R. Goodacre, *Anal. Chem.*, 2017, **89**, 2472–2477.
- 55 J. Lin, Z. Huang, X. Lin, Q. Wu, K. Quan, Y. Cheng, M. Zheng, J. Xu, Y. Dai and H. Qiu, *Biomed. Opt. Express*, 2020, **11**, 7109–7119.
- 56 J. Langer, D. Jimenez de Aberasturi, J. Aizpurua, R. A. Alvarez-Puebla, B. Auguie, J. J. Baumberg, G. C. Bazan, S. E. J. Bell, A. Boisen, A. G. Brolo, J. Choo, D. Cialla-May, V. Deckert, L. Fabris, K. Faulds, F. J. G. de Abajo, R. Goodacre, D. Graham, A. J. Haes, C. L. Haynes, C. Huck, T. Itoh, M. Käll, J. Kneipp, N. A. Kotov, H. Kuang, E. C. Le Ru, H. K. Lee, J.-F. Li, X. Y. Ling, S. A. Maier, T. Mayerhöfer, M. Moskovits, K. Murakoshi, J.-M. Nam, S. Nie, Y. Ozaki, I. Pastoriza-Santos, J. Perez-Juste, J. Popp, A. Pucci, S. Reich, B. Ren, G. C. Schatz, T. Shegai, S. Schlücker, L.-L. Tay, K. G. Thomas, Z.-Q. Tian, R. P. van Duyne, T. Vo-Dinh, Y. Wang, K. A. Willets, C. Xu, H. Xu, Y. Xu, Y. S. Yamamoto, B. Zhao and L. M. Liz-Marzán, *ACS Nano*, 2020, **14**, 28–117.
- 57 R. D. Norton, H. T. Phan, S. N. Gibbons and A. J. Haes, *Annu. Rev. Phys. Chem.*, 2022, **73**, 141–162.
- 58 S. E. Bell, G. Charron, E. Cortés, J. Kneipp, M. L. de la Chapelle, J. Langer, M. Procházka, V. Tran and S. Schlücker, *Angew. Chem., Int. Ed.*, 2020, **59**, 5454–5462.

